Use of ebselen as a neuroprotective agent in rat spinal cord subjected to traumatic injury

Ślusarczyk, Wojciech; Olakowska, Edyta; Larysz‐Brysz, Magdalena; Woszczycka-Korczyńska, Izabella; Carrillo, Daria Gendosz de; Węglarz, Władysław P.; Lewin–Kowalik, Joanna; Marcol, Wiesław

doi:10.4103/1673-5374.251334

Cited by 8 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the pioneering study of Ünlü et al ( 2002 ), the neuroprotective effects of ebselen on a spinal cord injury (SCI) model have been investigated. Applying the same dose (Aras et al 2014 ; Jia et al 2018 ; Kalayci et al 2005 ) but an SCI model quite different from other studies, ebselen was proven to have a limited beneficial effect on the regeneration of the injury in the spinal cord white matter of rats (Ślusarczyk et al 2019 ). Conversely, the improvement of motor function 14 days after the injury and the raise of anti-apoptotic and antioxidant markers had been previously reported (Jia et al 2018 ; Kalayci et al 2005 ).…”

Section: Pharmacology Of Organoselenium Compoundsmentioning

confidence: 99%

“…Conversely, the improvement of motor function 14 days after the injury and the raise of anti-apoptotic and antioxidant markers had been previously reported (Jia et al 2018 ; Kalayci et al 2005 ). The authors suggest that these conflicting outcomes are explained by the fact that the neuroprotective effects of ebselen are not persistent long time after the administration (Ślusarczyk et al 2019 ).…”

Section: Pharmacology Of Organoselenium Compoundsmentioning

confidence: 99%

See 1 more Smart Citation

Toxicology and pharmacology of synthetic organoselenium compounds: an update

2021

View full text Add to dashboard Cite

Here, we addressed the pharmacology and toxicology of synthetic organoselenium compounds and some naturally occurring organoselenium amino acids. The use of selenium as a tool in organic synthesis and as a pharmacological agent goes back to the middle of the nineteenth and the beginning of the twentieth centuries. The rediscovery of ebselen and its investigation in clinical trials have motivated the search for new organoselenium molecules with pharmacological properties. Although ebselen and diselenides have some overlapping pharmacological properties, their molecular targets are not identical. However, they have similar anti-inflammatory and antioxidant activities, possibly, via activation of transcription factors, regulating the expression of antioxidant genes. In short, our knowledge about the pharmacological properties of simple organoselenium compounds is still elusive. However, contrary to our early expectations that they could imitate selenoproteins, organoselenium compounds seem to have non-specific modulatory activation of antioxidant pathways and specific inhibitory effects in some thiol-containing proteins. The thiol-oxidizing properties of organoselenium compounds are considered the molecular basis of their chronic toxicity; however, the acute use of organoselenium compounds as inhibitors of specific thiol-containing enzymes can be of therapeutic significance. In summary, the outcomes of the clinical trials of ebselen as a mimetic of lithium or as an inhibitor of SARS-CoV-2 proteases will be important to the field of organoselenium synthesis. The development of computational techniques that could predict rational modifications in the structure of organoselenium compounds to increase their specificity is required to construct a library of thiol-modifying agents with selectivity toward specific target proteins.

show abstract